Correction to: Metabolomic profiling identifies distinct phenotypes for ASS1 positive and negative GBM

Lina Mörén; Richard Perryman; Tim Crook; Julia K Langer; Kevin Oneill; Nelofer Syed; Henrik Antti

doi:10.1186/s12885-018-4128-9

Correction to: Metabolomic profiling identifies distinct phenotypes for ASS1 positive and negative GBM

BMC Cancer. 2018 Mar 8;18(1):268. doi: 10.1186/s12885-018-4128-9.

Authors

Lina Mörén¹, Richard Perryman², Tim Crook³, Julia K Langer², Kevin Oneill², Nelofer Syed⁴, Henrik Antti⁵

Affiliations

¹ Department of Chemistry, Umeå University, SE 901 87, Umeå, Sweden.
² John Fulcher Neuro-Oncology Laboratory, Imperial College London, London, UK.
³ St Luke's Cancer Centre, Royal Surrey County Hospital, Guildford, Surrey, UK.
⁴ John Fulcher Neuro-Oncology Laboratory, Imperial College London, London, UK. n.syed@imperial.ac.uk.
⁵ Department of Chemistry, Umeå University, SE 901 87, Umeå, Sweden. henrik.antti@umu.se.

Abstract

In the original publication of this article [1], published on 8 February 2018, it was noticed that the acknowledgement of the source of the drug ADI-PEG20 was missing.

Publication types

Published Erratum